Fundraising & IPO Readiness
Build an IP position and value narrative that can withstand investor, underwriter and regulatory scrutiny.
Corporate IP Strategy for Biotech & PharmaCWIP / Corporate IP Strategist / Biotech & Pharma
IP strategy for enterprise value.
Before the market sees the opportunity, complete the strategy that will protect it.
CWIP advises biotech and pharmaceutical leaders on aligning intellectual property with fundraising, IPO readiness, licensing, due diligence and global growth.
Founder & Principal AdvisorDr. Chih-Wei Wu
Board-level perspectiveBiotech & pharmaceutical depthCross-border execution
FundraisingTurn IP into an investable value story
IPOPrepare the portfolio for market scrutiny
Licensing & DDStrengthen leverage before the deal table
Global GrowthPosition before competition begins
The CWIP perspective
Design intellectual property from the endgame backward.
A patent is valuable only when it supports the future the company is trying to build.
CWIP begins with the corporate objective: financing, IPO, licensing, market entry or competitive defense. We then work backward to determine what the business must protect, what evidence must be built and how the portfolio should be designed.
Filing and prosecution are handled with trusted patent firms. CWIP remains focused on the higher-order question: whether the strategy will create leverage when the company is evaluated in the real world.
Strategic mandates
For the moments that determine enterprise value.
Advisory work shaped around the decisions biotech chairpersons, CEOs, boards and investors cannot afford to revisit too late.
Licensing & Due Diligence
Enter negotiations with a clear view of asset quality, competitive leverage, hidden gaps and transaction risk.
R&D & Portfolio Strategy
Align scientific investment, product direction and patent architecture before resources become locked in.
Global Market Positioning
Use patent intelligence to anticipate competitors, select markets and design a defensible path to growth.
Valuation & Deal Support
Translate technology and IP into evidence that supports valuation, partnership and board-level decisions.
Dispute Readiness
Pressure-test critical rights against infringement, invalidity and enforcement realities before they are challenged.
Our operating belief
The future of a company is not decided when competition begins. It is decided when positioning begins.
Think before acting. Position before competing.
Strategic method
From foresight to defensible value.
A disciplined path connecting scientific insight, business direction and IP architecture.
Read the field before the market does.
Map science, competitors, patents, market movement and transaction signals to expose both opportunity and risk.
Choose where the company must win.
Connect corporate ambition with R&D priorities, capital strategy, target markets and the realities of execution.
Build IP around the business endgame.
Shape claims, portfolio structure, trade secrets and governance around future licensing, financing and competition.
Prepare value to be tested under pressure.
Make the strategy legible and defensible when investors, partners, courts or counterparties examine it.
Why CWIP
Experience from where IP is truly tested.
Dr. Chih-Wei Wu brings more than two decades across biotechnology, pharmaceutical strategy, licensing negotiation, technology valuation, patent intelligence and disputes.
This endgame experience shapes the advice given at the beginning: how to direct research, design patents and keep business strategy aligned with intellectual property before capital and competitive pressure expose the gaps.
1,000+global patent applications managed
100+patent intelligence engagements
50+technology valuation projects
Credibility across disciplines
Science, law and enterprise execution in one advisory perspective.
The ability to move between the laboratory, legal analysis, capital conversations and the executive agenda is central to every CWIP engagement.
Academic foundation
Ph.D., Biotechnology
National Tsing Hua University
LL.M., Technology Law
Soochow University School of Law
M.S., Biotechnology
National Tsing Hua University
B.S., Biology
Tunghai University
Current appointments / 現職
US Apollomics (NASDAQ: APLM)
IP Advisor
陽明賦活再生醫學
智財顧問
國家衛生研究院育成中心
智財顧問
經濟部中小企業處
企業智權輔導顧問
Leadership & professional experience / 經歷
北極星藥業集團 KY Polaris Group (TWSE 6550)
法務主管
北極星藥業集團 KY Polaris Group (TWSE 6550)
智財長
北極星藥業集團 KY Polaris Group (TWSE 6550)
資安長
德勤商務法律事務所（勤業眾信集團 Deloitte）
協理
中華智慧資產經營管理協會
秘書長
戰國策智權事務所
共同創辦人
國立清華大學校友總會
常務監事
國立清華大學生命科學系校友會
會長
國立清華大學新創事業創業競賽
評審委員
清華天使創投
投資審議委員
國際 BNI 商會核心 8 長
成長協調員
Selected qualifications
Governance and transaction credentials that support board-level advice.
Knowledge in action
Strategic ideas tested through practice and dialogue.
More than 200 invited talks for industry, government, research institutes and universities on biotechnology patent strategy, valuation, governance and AI-powered patent intelligence.
Explore speaking & eventsSelected research
Scientific depth. Strategic application.
- 01
Patent layout strategies for biotechnology and pharmaceuticals - LL.M. thesis, Soochow University School of Law, 2022.
- 02
Solution structure and neutralizing antibody binding studies of domain III of the dengue-2 virus envelope protein - Proteins, 2008.
- 03
Structural basis of a flavivirus recognized by its neutralizing antibody - Journal of Biological Chemistry, 2003.
A conversation before the next move